SAMPLE SIZES
Sample sizes for diversity analyses:
  Inversion callset columns indicate 44 phased individuals (sample columns).
  Reporting haplotypes as twice the sample count yields 88 potential phased haplotypes.
  Loci with ≥2 haplotypes per orientation for π: 60 (from output.csv).
  High-quality inversions with consensus recurrence calls: 93 total (single-event = 61, recurrent = 32).

DIVERSITY
Nucleotide diversity (π) by orientation and recurrence:
  Total loci with finite π estimates: 67.
  Across all loci: mean π(inverted) = 0.000273, mean π(direct) = 0.000387.
    Two-sided paired t-test comparing orientations: t = -2.870, p = 5.505e-03.
  Single-event inversions: median π(inverted) = 6.000000e-06, median π(direct) = 0.000233.
  Recurrent inversions: median π(inverted) = 0.000359, median π(direct) = 0.000442.
  Within inverted haplotypes: recurrent median π = 0.000359; single-event median π = 6.000000e-06.

LINEAR MODEL
Orientation × recurrence linear model on log π ratios (Model A):
  Detection floor ε before log transform: 6.325000e-06.
  Single-event: Inverted vs Direct: fold-change = 0.279 (95% CI 0.151–0.515), p = 4.427e-05.
  Recurrent: Inverted vs Direct: fold-change = 1.099 (95% CI 0.905–1.336), p = 0.341.
  Interaction (difference between those two): fold-change = 3.941 (95% CI 2.072–7.497), p = 2.910e-05.
  Overall inversion effect (pooled Δ-logπ): fold-change = 0.537 (95% CI 0.372–0.776), p = 9.424e-04.

DIFFERENTIATION
Differentiation between orientations (Hudson's FST):
  Single-event: median FST = 0.325 (n = 28).
  Recurrent: median FST = 0.070 (n = 32).
  Mann–Whitney U test (single-event vs recurrent): U = 628.000, p = 7.680e-03.
  Highly differentiated loci: 26 with FST > 0.2 and 10 with FST > 0.5.

BREAKPOINT FRF
Breakpoint enrichment (flat–ramp–flat model deltas):
  Single-event: mean flank–middle FST difference = 0.043 (n = 14).
  Recurrent: mean flank–middle FST difference = -0.079 (n = 17).
  Difference in edge enrichment (single-event − recurrent): Δ = 0.122.

PHEWAS SCALE
PheWAS scale and coverage:
  Unique phecodes tested: 1089.
  Case counts span 1002–137692; controls span 182133–368254.
  Phenotype coverage per inversion (top five): chr10-79542902-INV-674513: 1089, chr12-46897663-INV-16289: 1089, chr17-45585160-INV-706887: 1089, chr4-33098029-INV-7075: 1089, chr6-141867315-INV-29159: 1089; ....
  Inversions with ≥1 BH-significant association: 4 of 6.

KEY ASSOCIATIONS
Selected inversion–phenotype associations (logistic regression with LRT p-values):
  chr10-79542902-INV-674513: no PheWAS results available locally for Positive DNA test for high-risk HPV types.
  chr6-141867315-INV-29159: no PheWAS results available locally for Laryngitis and tracheitis.
  chr12-46897663-INV-16289: no PheWAS results available locally for Conjunctivitis.
  chr12-46897663-INV-16289: no PheWAS results available locally for Migraine.
  chr17-45974480-INV-29218 vs Morbid obesity: OR = 1.054, 95% CI 1.031–1.078, BH-adjusted p ≈ 8.151e-04 (raw p = 3.650e-06).
  chr17-45974480-INV-29218 vs Breast lump or abnormal exam: OR = 0.956, 95% CI 0.936–0.977, BH-adjusted p ≈ 6.375e-03 (raw p = 4.280e-05).
  chr17-45974480-INV-29218 vs Abnormal mammogram: OR = 0.939, 95% CI 0.910–0.969, BH-adjusted p ≈ 7.326e-03 (raw p = 6.870e-05).

CATEGORY TESTS
Phecode category omnibus tests (GBJ/GLS):
  chr12-46897663-INV-16289: Gastrointestinal (GBJ p=2.000e-05, GLS p=9.320e-05), Genitourinary (GBJ p=2.000e-05, GLS p=1.817e-04), Neoplasms (GBJ p=2.000e-05, GLS p=1.500e-04), Dermatological (GBJ p=2.000e-05, GLS p=2.410e-06), Symptoms (GBJ p=8.570e-05, GLS p=1.390e-04), Sense organs (GBJ p=1.143e-04, GLS p=9.060e-03), Muscloskeletal (GBJ p=2.000e-04, GLS p=0.057), Endocrine/Metab (GBJ p=1.600e-03, GLS p=1.688e-03), Respiratory (GBJ p=1.600e-03, GLS p=9.401e-03), Neurological (GBJ p=0.012, GLS p=0.308), Cardiovascular (GBJ p=0.132, GLS p=0.030), Mental (GBJ p=0.386, GLS p=0.036)
  chr17-45585160-INV-706887: Symptoms (GBJ p=2.000e-05, GLS p=2.239e-04), Neoplasms (GBJ p=2.000e-05, GLS p=5.800e-05), Dermatological (GBJ p=2.000e-05, GLS p=1.380e-03), Gastrointestinal (GBJ p=3.999e-04, GLS p=9.044e-03), Neurological (GBJ p=3.999e-04, GLS p=0.068), Endocrine/Metab (GBJ p=5.999e-04, GLS p=0.107), Respiratory (GBJ p=7.998e-04, GLS p=0.044), Sense organs (GBJ p=2.999e-03, GLS p=0.171), Muscloskeletal (GBJ p=4.599e-03, GLS p=0.033), Cardiovascular (GBJ p=0.013, GLS p=0.615), Blood/Immune (GBJ p=0.170, GLS p=0.010)
  chr4-33098029-INV-7075: Blood/Immune (GBJ p=0.112, GLS p=0.038), Respiratory (GBJ p=0.199, GLS p=0.029)
  chr6-141867315-INV-29159: Blood/Immune (GBJ p=0.025, GLS p=0.712), Respiratory (GBJ p=0.044, GLS p=0.625)
  chr6-167181003-INV-209976: Infections (GBJ p=0.369, GLS p=7.906e-03)

PGS CONTROLS
Effect of regional polygenic score controls:
  Lump_or_mass_in_breast_or_nonspecific_abnormal_breast_exam (chr17-45585160-INV-706887): p without PGS = 1.151e-04, with PGS = 6.380e-05; OR with controls = 0.883.
  Abnormal_mammogram (chr17-45585160-INV-706887): p without PGS = 1.892e-04, with PGS = 3.157e-04; OR with controls = 0.853.
  Overweight_and_obesity (chr17-45585160-INV-706887): p without PGS = 9.660e-07, with PGS = 3.265e-04; OR with controls = 1.058.
  Obesity (chr17-45585160-INV-706887): p without PGS = 1.240e-06, with PGS = 5.093e-04; OR with controls = 1.056.
  Morbid_obesity (chr17-45585160-INV-706887): p without PGS = 7.940e-09, with PGS = 8.476e-03; OR with controls = 1.059.
  Mild_cognitive_impairment (chr17-45585160-INV-706887): p without PGS = 2.087e-04, with PGS = 0.012; OR with controls = 0.798.
  Diastolic_heart_failure (chr17-45585160-INV-706887): p without PGS = 3.820e-05, with PGS = 0.038; OR with controls = 1.083.
  Malignant_neoplasm_of_the_breast (chr17-45585160-INV-706887): p without PGS = 3.666e-03, with PGS = 0.095; OR with controls = 0.907.
  Dementias (chr17-45585160-INV-706887): p without PGS = 0.789, with PGS = 0.494; OR with controls = 0.934.
  Alzheimers_disease (chr17-45585160-INV-706887): p without PGS = 0.415, with PGS = 0.743; OR with controls = 0.934.
  Largest p-value magnitude change: Lump_or_mass_in_breast_or_nonspecific_abnormal_breast_exam (fold-change ≈ 1.804).

SELECTION
Ancient DNA selection summary (AGES trajectories):
  Largest predicted allele-frequency change over a 1,000-year window occurs between 0 and 1e+03 years BP (Δ ≈ 6.710e-03).
